Beta-phenyl-beta-alanine prevents the activation of vagal efferent discharges evoked by baclofen and GABA in rats.
The effects of DL-beta-phenyl-beta-alanine (BPBA) on vagal efferent discharges elicited by gamma-aminobutyric acid (GABA) and baclofen were investigated in rats. When given alone, BPBA (40 mg/kg, i.v.) caused no significant change in vagal nerve response and did not elicit any convulsions. Pretreatment with BPBA (40 mg/kg, i.v.) resulted in 70% and 80% reductions in the vagal efferent discharges induced by GABA (400 mg/kg, i.v.) and baclofen (4 mg/kg, s.c.), respectively. The present results suggest that BPBA may be a novel GABA antagonist with respect to vagal activation mechanisms in the CNS.
Yamasaki
K
K
Department of Pharmacology, Tokushima Bunri University, Japan.
Goto
Y
Y
D000818:Animals; D001418:Baclofen / Q000037:antagonists & inhibitors*; D018756:GABA Antagonists; D007275:Injections, Intravenous; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009476:Neurons, Efferent / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D014630:Vagus Nerve / Q000187:drug effects* / Q000502:physiology; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology
C024799:2-phenyl-3-aminopropanoic acid; D018756:GABA Antagonists; D015091:beta-Alanine; D001418:Baclofen